Korean J Transplant.  2022 Nov;36(Supple 1):S163. 10.4285/ATW2022.F-2841.

Stereotactic body radiation as pretransplant locoregional therapy for hepatocellular carcinoma presenting beyond University of California San Francisco criteria: a report of three cases

• Liu YL
• Wang CC
• Huang BS
• Cheng JY
• Lin CC
• Lee WF
• Hung KC
• Lin YC
• Tzeng WJ

• KMID: 2535679
• DOI: http://doi.org/10.4285/ATW2022.F-2841

Abstract

Liver transplantation (LT) remains an effective treatment modality for patients with hepatocellular carcinoma (HCC). For those beyond University of California San Francisco criteria, locoregional therapy to reduce tumor burden and downstage to fall within the criteria is widely accepted. For advanced tumors with larger size or portal vein (PV) involvement ineligible for radiofrequency ablation (RFA) or transarterial chemoembolization (TACE), radiotherapy (RT) has shown to be effective for tumor control. Proton beam therapy (PBT) is an emerging form of RT for HCC, carrying less risk of radiation-induced liver disease with its excellent dose distribution. Due to its rarity and novelty, limited literature has discussed the potential role of PBT for pretransplant locore-gional therapy. In this article, we present two cases who received PBT prior to LT, and one case who endured stereotactic body radiation (SBRT).